FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

## **OMB APPROVAL** OMB Number: 3235-0287

Estimated average burden 0.5 hours per response:

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 5	ecuc	)II 3U(	n) or the	investment	Con	ірапу Асі	01 1940								
1. Name and Address of Reporting Person*  Blumenkranz Mark S.						2. Issuer Name <b>and</b> Ticker or Trading Symbol IVERIC bio, Inc. [ ISEE ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 07/11/2023										Officer (give title below)			specify	
C/O IVERIC BIO, INC. 8 SYLVAN WAY				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)						
(Street)				-											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
PARSIPPANY NJ 07054				Rule 10b5-1(c) Transaction Indication																
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Tab	le I - Nor	n-Deriv	ative	Sec	curit	ies Ac	quired, E	Disp	osed c	of, or E	Bene	eficial	ly Owned	t				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. r) 8)					Securition Benefici Owned I	Beneficially Owned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	( <i>A</i>	) or )	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 07/11/2						2023		D		32,08	088		(1)		0		D			
		1							uired, Di s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisable a Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative (Instr. 3 and				9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C S Illy C C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	O N O	umber						
Restricted Stock Units	(2)	07/11/2023			D			5,000	(3)		(3)	Commo	n 5	5,000	(3)	0		D		
Restricted Stock Units	(2)	07/11/2023			D			7,500	(3)		(3)	Commo	n 7	7,500	(3)	0		D		
Stock Option (Right to Buy)	\$4.48	07/11/2023			D			31,000	(4)	07	7/14/2030	Commo Stock	<sup>n</sup> 3	1,000	(4)	0		D		
Stock Option (Right to Buy)	\$6.82	07/11/2023			D			15,500	(4)	05	5/18/2031	Commo Stock	<sup>n</sup> 1	5,500	(4)	0		D		
Stock Option (Right to	\$9.94	07/11/2023			D			23,186	(4)	05	5/11/2032	Commo		3,186	(4)	0		D		

## **Explanation of Responses:**

- 1. On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common Stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive \$40.00 in cash, without interest and less any applicable withholding taxes
- 2. Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
- 3. Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) \$40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
- 4. Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than \$40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of \$40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price \$40.00 or greater was cancelled with no consideration payable in respect thereof.

/s/ Todd D.C. Anderman, as Attorney-in-Fact for Mark S. Blumenkranz

\*\* Signature of Reporting Person Date

07/13/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.